Singapore, Dec. 12 -- As part of this first-of-its-kind partnership between the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Singapore's Health Sciences Authority (HSA), companies will have a coordinated fast track pathway to engage both regulators at the same time. Under the new corridor, developers will be able to seek joint advice from both regulators early, helping them plan ahead and design better clinical trials, avoid duplication and reduce delays.

Published by HT Digital Content Services with permission from BioSpectrum Asia....